RT @cvirendo: Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy &…
RT @cvirendo: Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy &…
RT @cvirendo: Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy &…
RT @cvirendo: Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy &…
RT @RKTvascular: In the old days, success of treatment for intermittent claudication was reported as “improvement of walking distance” and…
RT @cvirendo: Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy &…
RT @cvirendo: Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy &…
RT @cvirendo: Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy &…
RT @RKTvascular: Success of treatment is now, always, reported by various pseudo/proxy endpoints. TLR (target lesion revascularisation), pa…
RT @RKTvascular: In the old days, success of treatment for intermittent claudication was reported as “improvement of walking distance” and…
RT @RKTvascular: In the old days, success of treatment for intermittent claudication was reported as “improvement of walking distance” and…
RT @RKTvascular: In the old days, success of treatment for intermittent claudication was reported as “improvement of walking distance” and…
RT @RKTvascular: Success of treatment is now, always, reported by various pseudo/proxy endpoints. TLR (target lesion revascularisation), pa…
RT @RKTvascular: An immediate general agreement among all stakeholders that there should be more focus on meaningful clinical endpoints in…
RT @RKTvascular: In the old days, success of treatment for intermittent claudication was reported as “improvement of walking distance” and…
Success of treatment is now, always, reported by various pseudo/proxy endpoints. TLR (target lesion revascularisation), patency and LLL (late lumen loss) are the parameters for success today instead of the clinical outcomes that really make sense for a pat
In the old days, success of treatment for intermittent claudication was reported as “improvement of walking distance” and success of treatment for critical ischaemia was reported as “prevention of amputation n wound healing”, clinical outcomes that matter
An immediate general agreement among all stakeholders that there should be more focus on meaningful clinical endpoints in reporting new endovascular data is an un- avoidable and urgently needed first step for self- regulation. Well said!
RT @cvirendo: Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy &…
RT @CREEurope: Wise words from a giant of interventional radiology. @CAIRads @RMargau @UofTVascular @OslerVascular https://t.co/7G4IyuVnul
Wise words from a giant of interventional radiology. @CAIRads @RMargau @UofTVascular @OslerVascular
RT @AtulGupta_MD: Hear from Prof Jim Reekers @cvirendo explain how trials need to measure clinical outcomes that truly matter to the patien…
Challenges of new Endovascular technologies are numerous: New European regulations, costs, reimbursement, defining efficacy & replacing established older technologies are just some of the hurdles before a new technique becomes part of our daily IR tool